Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer

This trial is studying a combination of chemotherapy drugs delivered directly into the liver's blood supply (a technique called hepatic artery infusion, or HAIC) for people with pancreatic cancer that has spread only to the liver. The goal is to find out whether this approach works better than standard chemotherapy after previous treatments have stopped working. **You may be eligible if...** - You are 18 or older with pancreatic cancer that has spread only to the liver - Previous standard chemotherapy (AG regimen) has stopped working or caused intolerable side effects - Your overall health and organ function meet certain minimum levels (blood counts, liver and kidney function within acceptable ranges) - You are reasonably functional day-to-day (ECOG score 0–2) **You may NOT be eligible if...** - Your cancer has spread to organs other than the liver - You have significant fluid buildup in your abdomen (ascites) that needs treatment - You have serious heart disease, active hepatitis B, or active infection - You are pregnant or breastfeeding - Your estimated survival is 3 months or less Talk to your doctor to see if this trial is right for you.